Showing results (121-130 of 408) with videos related to

Sort By:
Pageof 41
Journal of Personalized Medicine|November 27, 2021
Quantitative Imaging Biomarkers in Age-Related Macular Degeneration and Diabetic Eye Disease: A Step Closer to Precision MedicineGagan Kalra, Sudeshna Sil Kar, Duriye Damla Sevgi, et al.
IEEE Transactions on Bio-Medical Engineering|August 22, 2020
Imaging Features of Vessels and Leakage Patterns Predict Extended Interval Aflibercept Dosing Using Ultra-Widefield Angiography in Retinal Vascular Disease: Findings From the PERMEATE StudyAzam Moosavi, Natalia Figueiredo, Prateek Prasanna, et al.
Eye (London, England)|May 28, 2024
ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathyQuan Dong Nguyen, Justis P Ehlers, David S Boyer, et al.
Retina (Philadelphia, Pa.)|June 26, 2009
Strategies for inhibiting vascular endothelial growth factorPeter K Kaiser
Retina (Philadelphia, Pa.)|June 26, 2009
Overview of radiation trials for age-related macular degenerationPeter K Kaiser
Current Medical Research and Opinion|June 23, 2005
Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effectPeter K Kaiser
Ophthalmology|May 7, 2013
Emerging therapies for neovascular age-related macular degeneration: drugs in the pipelinePeter K Kaiser
American Journal of Ophthalmology|October 3, 2006
Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseasesPeter K Kaiser
Current Medical Research and Opinion|June 18, 2009
Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trialPeter K Kaiser,
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|March 16, 2006
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8Peter K Kaiser,
Pageof 41